Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Fukuda H, et al. Among authors: shimada m. Cancer Sci. 2024 Jun;115(6):1763-1777. doi: 10.1111/cas.16154. Epub 2024 Mar 25. Cancer Sci. 2024. PMID: 38527308 Free PMC article.
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Nishizawa T, Fukuda H, Ohashi K, Arai K, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Maruyama T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Mizuno H, Tsunoda H, Ochiai A. Aoki K, et al. Among authors: shimada m. Cancer Res Commun. 2023 Jun 13;3(6):1026-1040. doi: 10.1158/2767-9764.CRC-22-0415. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377611 Free PMC article.
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, Yoshimoto M, Miura-Okuda M, Uchikawa R, Kato C, Shinozuka J, Akai S, Naoi S, Tomioka N, Nagaya N, Pang CL, Garvita G, Feng S, Shimada M, Kamata-Sakurai M, Aburatani H, Kitazawa T, Igawa T. Kamikawa T, et al. Among authors: shimada m. J Immunother Cancer. 2024 Oct 14;12(10):e009563. doi: 10.1136/jitc-2024-009563. J Immunother Cancer. 2024. PMID: 39401967 Free PMC article.
Returning genetic risk information for hereditary cancers to participants in a population-based cohort study in Japan.
Ohneda K, Suzuki Y, Hamanaka Y, Tadaka S, Shimada M, Hasegawa-Minato J, Takahashi M, Fuse N, Nagami F, Kawame H, Kobayashi T, Yamaguchi-Kabata Y, Kinoshita K, Nakamura T, Ogishima S, Kumada K, Kudo H, Kuriyama SI, Izumi Y, Shimizu R, Tochigi M, Motonari T, Tokunaga H, Kikuchi A, Masamune A, Aoki Y, Ishioka C, Ishida T, Yamamoto M. Ohneda K, et al. Among authors: shimada m. J Hum Genet. 2025 Jan 17. doi: 10.1038/s10038-024-01314-w. Online ahead of print. J Hum Genet. 2025. PMID: 39825003
Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.
Kobayashi T, Hisamatsu T, Motoya S, Fujii T, Kunisaki R, Shibuya T, Matsuura M, Takeuchi K, Hiraoka S, Yasuda H, Yokoyama K, Takatsu N, Maemoto A, Tahara T, Tominaga K, Shimada M, Kuno N, Fernandez JL, Ishiguro K, Cavaliere M, Deguchi H, Hibi T. Kobayashi T, et al. Among authors: shimada m. Intest Res. 2025 Jan 16. doi: 10.5217/ir.2024.00063. Online ahead of print. Intest Res. 2025. PMID: 39818201 Free article.
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.
Taniguchi Y, Tamiya A, Osuga M, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Shimada M, Ando M, Koh Y. Taniguchi Y, et al. Among authors: shimada m. Invest New Drugs. 2025 Jan 9. doi: 10.1007/s10637-024-01500-9. Online ahead of print. Invest New Drugs. 2025. PMID: 39789369
3,296 results